|
|
| | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE Basic information |
| Product Name: | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE | | Synonyms: | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE;YL-109;4-(benzo[d]thiazol-2-yl)-2-Methoxyphenol;Y109;Y-109;Y-109;Y109;4-(3H-1,3-benzothiazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one;4-(1,3-Benzothiazol-2-yl)-2-methoxyphenol | | CAS: | 36341-25-0 | | MF: | C14H11NO2S | | MW: | 257.31 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 36341-25-0.mol |  |
| | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:9): 0.1 mg/ml; Ethanol: 1 mg/ml | | form | A crystalline solid |
| | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE Usage And Synthesis |
| Biological Activity | YL-109 is a novel antitumor agent that inhibits the growth and invasion of breast cancer cells in vitro and in vivo. | | in vitro | YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.
YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells. Cell Proliferation Assay | Cell Line: | < td class="col2"> MCF-7 and MDA-MB-231 cells | Concentration: | 0.001, 0.01, 0.1, 1, 10 μM | | Incubation Time: | 96 hours | | Result: | Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50 =85.8 nM and 4.02 μM, respectively). | | | in vivo | YL-109 (15 mg/kg; sc for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo. < /p> | Animal Model: | BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells | | Dosage: | 15 mg/kg | | Administration: < /td> | Sc every 2 days for 63 days | | Result: | Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. | |
| | 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE Preparation Products And Raw materials |
|